| Writing committee member | Employment | Honoraria/speaking/consulting | Speakers’ bureau | Research* | Fellowship support* | Ownership/partnership/ principal/ majority stockholder | Stock or stock options | Intellectual property/royalties | Other |
|---|---|---|---|---|---|---|---|---|---|
|
Aileen M. Ferrick, PhD, ACNP, RN, FHRS (Co‐Chair) |
White Plains Hospital, White Plains, New York | None | None | None | None | None | None | None | None |
|
Satish R. Raj, MD, MSCI, FHRS (Co‐Chair) |
University of Calgary, Calgary, Alberta, Canada |
0: Arena Pharmaceuticals 1: Amneal Pharmaceuticals 1: Argenx 1: Elsevier 1: Regeneron 1: Servier 1: Spire Learning |
None |
0: Theravance 3: Stand Up To POTS 4: Heart & Stroke 5: CIHR 5: Dysautonomia International |
None | None | None | None |
0: AAS 0: CCS 0: Dysautonomia International |
| Thomas Deneke, MD, PhD, FHRS (EHRA Vice‐Chair) | Heart Center Bad Neustadt, Bad Neustadt, Germany |
1: Abbott 1: Biotronik 1: Farapulse 1: Galaxy Medical, Inc. 1: Imricor |
None | None | None | None | None | None | 1: Boston Scientific |
| Pipin Kojodjojo, MBBS, PhD, FHRS (APHRS Vice‐Chair) | Asian Heart & Vascular Centre, Singapore | None | None | None | None | None | None | None | None |
| Nestor Lopez‐Cabanillas, MD (LAHRS Vice‐Chair) | Adventist Cardiovascular Institute, Buenos Aires, Argentina | None | None | None | None | None | None | None | None |
| Haruhiko Abe, MD, PhD | University of Occupational and Environmental Health Hospital, Kitakyushu, Japan | 1: Abbott Japan |
1: Boston Scientific Japan 1: Japan Medtronic, Inc. |
None | None | None | None | None | None |
| Felix A. Ayala‐Paredes, MD† | Universite de Sherbrooke Faculty Sherbrooke, Quebec, Canada | None | None | None | None | None | None | None | None |
| Serge Boveda, MD, PhD, FEHRA, FESC | Clinique Pasteur, Toulouse, France |
1: Boston Scientific 1: Microport CRM 1: Zoll Medical Corporation 2: Medtronic |
None | None | None | None | None | None | None |
| Derek S. Chew, MD, MSc, FHRS | University of Calgary, Calgary, Alberta, Canada | 1: UTI Limited Partnership (Innovate Calgary) | None | 4: CIHR | None | None | None | None | None |
| Jong‐Il Choi, MD, PhD, MHS | Korea University Medical Center, Seoul, Korea |
0: Abbott 0: Medtronic 1: Boehringer Ingelheim 1: Chong Kun Dang Pharmaceutical Corp 1: Daewoong Pharm 1: Daiichi Sankyo 1: Johnson & Johnson 1: Menarini Group 1: Novartis 1: Sanofi 1: Samjin Pharmaceutical Co, Ltd |
None |
0: Sanofi 5: Chong Kun Dang Pharmaceutical Corp |
None | None | None | None | None |
| Nikolaos Dagres, MD | Heart Center Leipzig at the University of Leipzig, Leipzig, Germany | None | None | None | None | None | None | None | 0: EHRA |
| Aarti S. Dalal, DO, FACC, FHRS, CEPS‐P | Vanderbilt University Medical Center, Nashville, Tennessee | 1: Medtronic | None | None | None | None | None | None | None |
| Brynn E. Dechert, APN, FHRS, CCDS | C.S. Mott Children's Hospital, Ann Arbor, Michigan | None | None | None | None | None | None | None | None |
| Camille G. Frazier‐Mills, MD, MHS, CCDS | Duke University Medical Center, Durham, North Carolina |
1: Boston Scientific 1: Johnson & Johnson 2: Medtronic |
None | None | None | None | None | None | None |
| Olivia Gilbert, MD, MSc, FACC | Wake Forest Baptist Medical Center, Winston‐Salem, North Carolina | None | None | None | None | None | None | None | None |
| Janet K. Han, MD, FACC, FHRS | VA Greater Los Angeles Healthcare System, Los Angeles, California | 1: Medtronic | None | None | None | None | None | None | None |
| Sherri Hewit, PharmD | None | None | None | None | None | None | None | None | |
| Christine Kneeland, BSN | Mayo Clinic, Rochester, Minnesota | None | None | None | None | None | None | None | None |
| Starr DeEllen Mirza | None | None | None | None | None | None | None | None | |
| Suneet Mittal, MD, FHRS | The Valley Hospital, Ridgewood, New Jersey |
1: Abbott 1: AltaThera Pharmaceuticals 1: ARCA Biopharma, Inc. 1: AtriCure, Inc. 1: Baylis Medical Company 1: Biosense Webster, Inc. 1: BMS / Pfizer Alliance 1: CathVision 1: CVRx Inc. 1: Haemonetics 1: Implicity 1: Impulse Dynamics USA 1: Octagos 2: Catawba 2: Philips 3: Boston Scientific 4: Medtronic |
None | None | None | None | None | None | None |
| Renato Pietro Ricci, MD | Cardio Arrhythmology Center, Rome, Italy |
0: Abbott 1: Dompé Farmaceutici S.p.A. |
None | None | None | None | None | None | None |
| Mary Runte, PhD | University of Lethbridge, Lethbridge, Alberta, Canada | None | None | None | None | None | None | None | None |
| Susan Sinclair, NZCS, PGDHSc | Auckland City Hospital, Auckland, New Zealand | None | None | None | None | None | None | None | None |
| Ricardo Alkmim‐Teixeira, MD, PhD | Hospital Renascentista, Pouso Alegre, Minas Gerais, Brazil |
1: Abbott 1: Bayer Healthcare Pharmaceuticals 1: Daiichi Sankyo 1: Spectranetics Corporation 1: Wyeth |
None | None | None | None | None | None | None |
| Bert Vandenberk, MD, PhD |
University of Calgary, Calgary, Alberta, Canada Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium |
None | None | None | 4: Frans Van de Werf Fund for Clinical Cardiovascular Research | None | None | None | None |
| Niraj Varma, MA, MD, PhD | Cleveland Clinic, Cleveland, Ohio |
0: Biotronik 0: Boston Scientific 0: Pacemate 1: EP Solutions 1: Implicity 1: Medtronic 2: Abbott 3: Impulse Dynamics USA |
None | None | None | None | None | None | None |
Number value: 0 = $0; 1 = ≤ $10,000; 2 = > $10,000 to ≤ $25,000; 3 = > $25,000 to ≤ $50,000; 4 = > $50,000 to ≤ $100,000; 5 = > $100,000.
This table is a comprehensive list of the relationships with industry and other entities (RWI)―regardless of relevance to the document topic―disclosed by each writing committee member for the 12 months prior to the initial meeting of the writing committee and up through the completion of the document. The table does not necessarily reflect the RWI of the writing committee members at the time of publication. Please refer to the HRS Code of Ethics and Professionalism for definitions of disclosure categories or additional information about the HRS policy on the disclosure of relationships with industry and other entities. To mitigate potential bias and conflict of interest, the recommendations and supportive text were written by writing committee members who were free of relevant RWI.
*Research and fellowship support are classed as programmatic support. Sources of programmatic support are disclosed but are not regarded as a relevant relationship with industry for writing group members or reviewers.
†Dr. Ayala‐Paredes stepped down from the writing committee in July 2022 when he developed a new role in industry, which precluded him from participation in the development of the document. Dr. Ayala‐Paredes was one of the authors for Section 9, Remote Monitoring Reporting. He left the writing committee before recommendations were developed in this section. After his departure, this section was re‐reviewed by the section lead/authors and the document chairs, and the evidence for this section was re‐reviewed by the document methodologists.
AAS = American Autonomic Society; CCS = Canadian Cardiovascular Society; CIHR = Canadian Institute of Health Research; EHRA = European Heart Rhythm Society.